Chosa Oncology is a pharmaceutical company. Today, the focus is on the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is a significant part of the business operations where the body's immune system is used to fight and eliminate cancer cells. The company's drug candidate is used in combination with surgery or radiation therapy. The company was established in 2007 and is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Buhl Krone Holding ApS | 24,70 | 24,70 | 2023-01-18 |
| Claus Frisenberg Pedersen | 11,68 | 11,68 | 2023-01-18 |
| Smerud Medical Research International AS | 8,45 | 8,45 | 2023-01-18 |
| IPO Nordic Fund A/S | 8,12 | 8,12 | 2023-01-18 |
| Rutger Arnhult | 6,19 | 6,19 | 2023-01-18 |
| Rq Solutions Aps | 2,11 | 2,11 | 2023-01-18 |
| Xiaoliang Wu | 1,44 | 1,44 | 2022-12-28 |
| Öyvind Vågen | 1,35 | 1,35 | 2022-12-28 |
| Avanza Pension | 1,28 | 1,28 | 2022-12-28 |
| Sara Shamloo Ekblad | 0,87 | 0,87 | 2022-12-28 |
2023-05-05 Delårsrapport 2023-Q1
2023-05-26 Årsstämma 2022
2023-08-28 Delårsrapport 2023-Q2
2023-11-10 Delårsrapport 2023-Q3
2024-02-09 Bokslutskommuniké 2023